Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension

Respiratory Research

Volumn 10, Issue , 2009, Pages

  Droste, Annette S ^a   Rohde, David ^a   Voelkers, Mirko ^a   Filusch, Arthur ^a   Bruckner, Thomas ^b   Borst, Mathias M ^a   Katus, Hugo A ^a   Meyer, F Joachim ^a  

^a Department of Cardiology Angiology and Respiratory Medicine ^*  (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR; SULFONAMIDE;

6 MINUTE WALK TEST; ADULT; AGED; AIRWAY DYNAMICS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EXERCISE INTENSITY; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG VOLUME; MALE; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RESIDUAL VOLUME; SYSTOLIC BLOOD PRESSURE; TOTAL LUNG CAPACITY; TREATMENT DURATION; VITAL CAPACITY; WALKING; AIRWAY OBSTRUCTION; CLINICAL TRIAL; DRUG ANTAGONISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PULMONARY ARTERY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AIRWAY OBSTRUCTION; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY ARTERY; RECEPTORS, ENDOTHELIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77449114890     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-10-129     Document Type: Article

References (30)

1. Simmeneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43:S5-S12.
2. Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J, et al. Peripheral airway obstruction in primary pulmonary hypertension. Thorax 2002, 57:473-476. 10.1136/thorax.57.6.473, 1746348, 12037220.
3. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension. Circulation 1970, 57:1163-1184.
4. Lai YL, Olson LW, Gillespie MN. Ventilatory dysfunction precedes pulmonary vascular changes in monocrotaline-treated rats. J Appl Physiol 1991, 70:561-566.
5. Sylvin H, Weitzberg E, Alving K. Endothelin-induced vascular and bronchial effects in pig airways: role in acute allergic responses. J Appl Physiol 2002, 93:1608-1615.
6. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333:214-221. 10.1056/NEJM199507273330403, 7540722.
7. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001, 120:1562-1569. 10.1378/chest.120.5.1562, 11713135.
8. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008, 31:407-415. 10.1183/09031936.00078207, 18238950.
9. Channick RN, Simmeneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001, 358:1119-1123. 10.1016/S0140-6736(01)06250-X, 11597664.
10. Rubin LJ, Simonneaux G, Barst RJ, Gahe N, Badesch DB, Black C. BREATHE-1 results of a multicenter, randomized, double-blind, placebo-controlled study of bosentan in pulmonary arterial hypertension (PAH). Arthritis and Rheumatism 2001, 44:S266.
11. Landgraf RG, Jancar S. Endothelin A receptor antagonist modulates lymphocyte and eosinophil infiltration, hyperreactivity and mucus in murine asthma. Int Immunopharmacol 2008, 8:1748-1753. 10.1016/j.intimp.2008.08.014, 18793757.
12. Burgess MI, Bright-Thomas RJ, Ray SG. Echocardiographic evaluation of right ventricular function. Eur J Echocardiogr 2002, 4:252-262.
13. Quanjer P. ECCS: standardized lung function testing. Bull Eur Physiopath Resp 1983, 19(Suppl 5).
14. Quanjer PH, Lebowitz MD, Gregg I, Miller MR, Pedersen OF. Peak expiratory flow: conclusions and recommendations of a Working Party of the European Respiratory Society. Eur Respir J Suppl 1997, 24:S2-S8.
15. American Thoracic Society ATS statement: guidelines for the six-minute walk test. Am J Resp Crit Care Med 2002, 166:111-117. American Thoracic Society.
16. Pride NB, Permutt S, Riley RL, Bromberger BB. Determinants of maximal expiratory flow from the lungs. J Appl Physiol 1967, 23:646-662.
17. Fernandez BP, Lupi HE, Martinez-Guerra ML, Barrios R, Seoane M, Sandoval J. Peripheral airways obstruction in idiopathic pulmonary artery hypertension. Chest 1983, 83:732-738. 10.1378/chest.83.5.732, 6839814.
18. Burke CM, Glanville AR, Morris AJ, Rubin D, Harvey JA, Theodore J, et al. Pulmonary function in advanced pulmonary hypertension. Thorax 1987, 42:131-135. 10.1136/thx.42.2.131, 460643, 3433237.
19. Spiekerkoetter E, Fabel H, Hoeper MM. Effects of inhaled salbutamol in primary pulmonary hypertension. Eur Respir J 2002, 20:524-528. 10.1183/09031936.02.02572001, 12358324.
20. O'Hagan AR, Stillwell PC, Arroliga A. Airway responsiveness to inhaled albuterol in patients with pulmonary hypertension. Clin Pediatr 1999, 38:27-33.
21. Galie N, Rubin LJ, Hoeper MM, Jansa P, Al Hiti H, Meyer GMB, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008, 371:2093-2100. 10.1016/S0140-6736(08)60919-8, 18572079.
22. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006, 27:589-595. 10.1093/eurheartj/ehi728, 16431875.
23. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006, 129:1313-1321. 10.1378/chest.129.5.1313, 16685024.
24. Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, et al. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. Regul Peptides 2008, 151:48-53.
25. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Resp Crit Care Med 2005, 171:1292-1297. 10.1164/rccm.200410-1411OC, 15750042.
26. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Resp Crit Care Med 2002, 165:398-405.
27. Xu SW, Chen YL, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004, 15:2707-2719. 10.1091/mbc.E04-08-0666, 420095, 15047866.
28. Finsnes F, Skjonsberg OH, Tonnessen T, Naess O, Lyberg T, Christensen G. Endothelin production and effects of endothelin antagonism during experimental airway inflammation. Am J Resp Crit Care Med 1997, 155:1404-1412.
29. Antus B, Sebe A, Fillinger J, Jeney C, Horvath I. Effects of blockade of the renin-angiotensin and endothelin systems on experimental bronchiolitis obliterans. J Heart Lung Transplant 2006, 25:1324-1329. 10.1016/j.healun.2006.08.007, 17097496.
30. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008, 32:619-628. 10.1183/09031936.00011308, 18448495.